Allogeneic hematopoietic cell transplantation for adult metachromatic leukodystrophy: a case series

• Published in: Blood advances 2024-03, Vol.8 (6), p.1504-1508
• Main Authors: Riedel, Andreas, Faul, Christoph, Reuss, Kristina, Schröder, Jan C., Lang, Peter J., Lengerke, Claudia, Weissert, Nadine, Hengel, Holger, Gröschel, Samuel, Schoels, Ludger, Bethge, Wolfgang A.
• Format: Article
• Language: English
• Subjects: Adult; Cerebroside-Sulfatase - genetics; Clinical Trials and Observations; Hematopoietic Stem Cell Transplantation; Humans; Leukodystrophy, Metachromatic - therapy
• ISSN: 2473-9529; 2473-9537; 2473-9537
• DOI: 10.1182/bloodadvances.2023011836

•Allo-HCT can be performed with tolerable side-effects, and successfully restores ARSA levels in adult patients with MLD.•Patients who achieved complete chimerism showed a clinically stable condition within the first year. [Display omitted] Metachromatic leukodystrophy (MLD) is a rare genetic disorder caused by pathogenic variants of the ARSA gene, leading to a deficiency of the arylsulfatase A enzyme (ARSA) and consecutive accumulation of galactosylceramide-3-0-sulfate in the nervous system. The condition leads to severe neurological deficits and subsequently results in profound intellectual and motoric disability. Especially, the adult form of MLD, which occurs in individuals aged >16 years, poses significant challenges for treating physicians because of the rarity of cases, limited therapeutic options, and different allogeneic hematopoietic cell transplantation (allo-HCT) protocols worldwide. Here, we report the results of allo-HCT treatment in 4 patients with a confirmed adult MLD diagnosis. Bone marrow or mobilized peripheral progenitor cells were infused after a reduced intensity conditioning regime consisting of fludarabine and treosulfan. In 3 patients, allo-HCT was followed by an infusion of mesenchymal cells to further consolidate ARSA production. We observed a good tolerability and an increase in ARSA levels up to normal range values in all patients. A full donor chimerism was detected in 3 patients within the first 12 months. In a 1-year follow-up, patients with complete donor chimerism showed a neurological stable condition. Only 1 patient with an increasing autologous chimerism showed neurological deterioration and a decline in ARSA levels in the first year. In summary, allo-HCT offers a therapeutic option for reconstituting ARSA enzyme levels in adult patients with MLD, with tolerable side effects.